Health Economic Perspectives and the Future of Cancer Treatments
Dr. Christopher Longo will provide a brief backgrounder on how and why economic evaluations are completed. He will discuss recent trends including guidance changes and help you understand how these changes might affect how and which cancer drugs are funded. He will also discuss how this might affect our future and what changes might need to be made.
Thursday October 4 2018
12:00 – 1:30 PM
DeGroote School of Business
Ron Joyce Centre, Room 429
4350 South Service Road
Burlington ON Canada L7L 5R8
Videoconferencing Option is Available *Please indicate interest during Registration
Adult $10, Parking Included, Transferrable
Flex Packages are available
Learn more about our speaker Dr. Christopher Longo
Christopher Longo, PhD, MSc, BA
Associate Professor, DeGroote School of Business, Health Policy and Management, Director, Health Services Management (MBA) & Member, Centre for Health Economics and Policy Analysis, McMaster University
Associate Professor (status only), Dalla Lana School of Public Health, University of Toronto
Co-Lead, Health Technology Assessment, Canadian Centre for Applied Research in Cancer Control
Dr. Longo has over 25 years’ experience in clinical research, economic evaluation and access strategies for pharmaceuticals. He has published clinical, economic, and policy research in a number of therapeutic areas including: cancer, diabetes, sepsis, and mental health disorders. He teaches courses in health economics and population health at McMaster, as well as a 5-week module on health economics in public health at the Dalla Lana School of Public Health at the University of Toronto (2009-2016). Longo’s research has examined the economics of cancer and diabetes, economic evaluation of pharmaceuticals, global pharmaceutical pricing strategies, the public/private mix in the financing of healthcare, and the evaluation of factors influencing patients’ financial burden for health care services. Although still interested in these issues and how they relate to the healthcare system and its end users, he has refocused his research agenda. His current research examines the costs and economic evaluation of interventions/programs throughout the cancer journey, with the intent of informing policy decision making.
Health Leadership Academy
With the generous funding of Michael G. DeGroote, the Faculties of Business and Health Sciences have come together to present the Health Leadership Academy (HLA). This Academy aligns closely with the mission, vision and values of its two founding Faculties, and will be specifically aimed at producing the best health leaders of tomorrow. To make a transformative impact on all levels of the health system the HLA will develop current and future health leaders with the capacity to identify, support and operationalize new ways of “thinking” and “doing” within a rapidly evolving health environment. The HLA’s goal is to be recognized as Canada’s preeminent Academy for health leadership and innovation with a reputation for creating and disseminating original work that intersects the areas of action-oriented learning, research and community engagement.
Our Collaboratorium Talks are intended to introduce new ways of thinking, projects and pedagogy in health leadership and innovation within the McMaster community and surrounding area.